Navigation Links
NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
Date:7/24/2009

rise significantly. We are very pleased to have this opportunity to research, develop and offer a new genetic test to help clients better diagnose and treat patients who may suffer from melanoma," said Douglas VanOort, Chairman and Chief Executive Officer for NeoGenomics.

With more than one million skin cancers diagnosed annually, distinguishing melanoma from other less severe forms of skin cancer is vital. In particular, it has been reported that current diagnostic tools and techniques for detecting cutaneous melanoma can be especially difficult in cases arising in association with a nevus (mole), and that 30-50% of cutaneous melanomas occur with an associated nevus. A FISH test for melanoma has the potential to improve existing diagnostic techniques in cases that are ambiguous, borderline or difficult to diagnose. NeoGenomics estimates that this new melanoma test represents a $50-$100 million annual revenue opportunity in the next 4-6 years.

"Influencing the existing cancer testing market in the US is a challenge, but all of us here at NeoGenomics believe the timing, scientific literature and market conditions are right for this new melanoma FISH test," said Robert Gasparini, President and Chief Scientific Officer of NeoGenomics. "We believe this new melanoma FISH test will complement our existing portfolio of FISH products. We also believe dermatopathologists will have a high level of interest in offering this test to their customers."

While this new test is still in the development phase, NeoGenomics currently anticipates bringing a FISH test to market in early 2010 after completing a rigorous validation process. In the event that Abbott develops and obtains FDA approval for its own FISH-based melanoma test, the Strategic Supply Agreement provides a means by which NeoGenomics may offer the FDA-approved test to its customers instead of the laboratory developed test being offered by NeoGenomics
'/>"/>

SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
2. NeoGenomics Announces Results for the 3rd Quarter 2007
3. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
4. NeoGenomics to Present at the Noble Financial Equity Conference
5. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
6. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. NeoGenomics Appoints Douglas M. VanOort as Executive Chairman and Interim Chief Executive Officer
8. NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009
9. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
10. NeoGenomics to Present at Noble Financials 5th Annual Equity Conference on Monday, June 8th
11. NeoGenomics Schedules Its Q2 2009 Earnings Release for July 28, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 As a board-certified ... his new offering of platelet-rich plasma (PRP) ... (MOSM) is known for its world-class care of ... extensive surgical experience lacking in many other physicians offering ... treatments are utilized for pain management and rehabilitation. Dr. ...
(Date:4/17/2015)... 2015 Baptist Health and The University ... partnership agreement designed to transform oncology care in northeast ... agreed to create a joint cancer program to enhance ... research. Baptist MD Anderson Cancer Center is anticipated to ... destination for highly coordinated, multidisciplinary cancer care for adults ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Connie Casad, ... and functional medicine advocate with 30 years of practice ... be adding another level of service for her patients ... website of 10 recommended wellness books with a brief ... asked to explain her interest in providing this service, ...
(Date:4/17/2015)... 17, 2015 Oxytocin is ... pituitary and thought to help mothers bond to their ... further substantiate this, new studies performed, at NYU Langone ... and reported by Medical News Today on April 16, ... over maternal social behavior. The study reveals that, when ...
(Date:4/17/2015)... NY (PRWEB) April 17, 2015 Ticket Down is ... for their 2015 Summer Tour. , The life of last-minute show ... see the popular group perform during the early part of 2015, ... “I Will Wait,” “Little Lion Man,” “The Cave,” and “Believe,” will ... off on June 2 at MCU Park at Coney Island in ...
Breaking Medicine News(10 mins):Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2
... to a report published in the December issue of the ... residents improved their knowledge of health care business concepts and ... expectation is for residents to "demonstrate an awareness of and ... as well as the ability to call effectively on other ...
... of synthetic molecules to fish for disease-specific antibodies, researchers have ... simple blood test. The same methodology might lead to blood ... the January 7th issue of the journal Cell , ... disease, it suggests it is a pretty general platform that ...
... study to date of "Sarcoid Like" Granulomatous Pulmonary Disease in ... of the condition was increased in this group as compared ... published online in the American Journal of Industrial Medicine ... responders who had an initial exam in the Mount Sinai ...
... the first robotic assisted surgery for prostate cancer in ... Vattikuti Institute. Today, the majority prostate of cancer ... than 6,000 procedures have been performed during the past ... field will meet at the world,s largest medical robotic ...
... most widely produced fruit in the world and now ... nutrient which could tackle the onset of vascular diseases. ... & Food Research , reveals that an extracted compound, ... led by Dr Teruo Kawada, from Kyoto University and ...
... brain against developing Alzheimer,s and other forms of dementia, according ... study, published in the academic journal Phytomedicine , also ... in protecting the body against cancer., Led by Dr Ed ... properties of green tea which have previously been shown ...
Cached Medicine News:Health News:Web-based curriculum improves surgical residents' knowledge of health care business 2Health News:A blood test for Alzheimer's disease? 2Health News:A blood test for Alzheimer's disease? 3Health News:Study of 'sarcoid-like' granulomatous pulmonary disease finds elevated rates in WTC responders 2Health News:Study of 'sarcoid-like' granulomatous pulmonary disease finds elevated rates in WTC responders 3Health News:10 years later: Robotic surgery for prostate cancer 2Health News:Protective properties of green tea uncovered 2
(Date:4/17/2015)... , April 17, 2015  In Detroit, where three ... mortality rate is two and one half times of the ... 6 of 10 infants that die in Detroit ... sobering statistics that Covenant Community Care, a faith-based, charitable non-profit ... poised to change thanks to a charitable donation by Konica ...
(Date:4/17/2015)... , April 17, 2015  Over the next five years, ... to grow, with ArcView predicting that 14 more states will ... marijuana. The U.S. market for legal cannabis grew 74 percent ... 2013. Analysts project the market could grow more than fourfold ... states soften their stance on marijuana. Cannabiz Mobile ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has announced ... in 2014 - a Perspective of Diabetes Patient Groups ... This independent study, funded by the author, represents ... in diabetes on the corporate reputation of 14 individual ... whole) in 2014. The results from the respondent diabetes ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
Designated most popular model or size. 4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Medicine Products: